Drug Trial Radar · NCT04663204
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 10, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- University of LeicesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Travere Therapeutics, Inc.
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and in (2: Cohort B) patients with recurrent IgAN following kidney transplantation.
Conditions
- Immunoglobulin A Nephropathy
- Kidney Diseases
- Glomerulonephritis, IGA
- Glomerulonephritis
- Autoimmune Diseases
- Immune System Diseases
Interventions
SparsentanDrug
Target dose of 400 mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urine protein/creatinine ratio (UP/C) at Week 36Time frame: Week 36
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Leicester General Hospital, University Hospitals of Leicester NHS Trust
Leicester, United Kingdom · Recruiting
King's College Hospital
London, United Kingdom · Recruiting
Cambridge University Hospitals NHS Trust
Cambridge, England, United Kingdom · Recruiting
Northern Care Alliance NHS Foundation Trust - Salford Royal
Salford, England, United Kingdom · Recruiting
Royal Infirmary of Edinburgh & Western General Hospital
Edinburgh, Scotland, United Kingdom · Recruiting
University Hospital of wales
Cardiff, Wales, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.